Baxter International Inc (BAX.N)
72.20USD
1 Aug 2013
$-0.84 (-1.15%)
$73.04
$73.50
$73.61
$72.03
870,800
804,431
$74.59
$57.40
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | $39,584.18 |
| Shares Outstanding (Mil.): | 541.95 |
| Dividend: | 0.49 |
| Yield (%): | 2.68 |
Financials
| BAX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.18 | 37.93 | 37.76 |
| EPS (TTM): | 4.02 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Baxter wins conditional EU clearance for Gambro takeover
BRUSSELS, July 22 - U.S. dialysis equipment maker Baxter International secured EU regulatory approval on Monday for its proposed $4 billion acquisition of Swedish peer Gambro AB after pledging to divest a unit to allay competition concerns.
EU to clear Baxter's $4 billion buy of Sweden's Gambro: sources
BRUSSELS - EU antitrust regulators will approve a $4 billion bid by Baxter International Inc for Sweden's Gambro AB after the U.S. company offered to sell a unit to ease competition concerns, two people familiar with the matter said on Wednesday.
UPDATE 2-EU to clear Baxter's $4 bln buy of Sweden's Gambro -sources
BRUSSELS, July 10 - EU antitrust regulators will approve a $4 billion bid by Baxter International Inc for Sweden's Gambro AB after the U.S. company offered to sell a unit to ease competition concerns, two people familiar with the matter said on Wednesday.
CORRECTED-UPDATE 1-EU to clear Baxter's $4 bln buy of Sweden's Gambro -sources
(Corrects first sentence to clarify that CRRT unit represents 2 percent of Baxter's renal product sales, instead of nearly 20 percent of Baxter's total sales.)
U.S. FDA approves new Baxter drug for hemophilia B
WASHINGTON - Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them.
U.S. FDA approves new Baxter drug for hemophilia B
WASHINGTON, June 27 - Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them.
Baxter's Alzheimer's disease drug fails in late-stage trial
NEW YORK - In a blow for Alzheimer's patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients.
UPDATE 2-Baxter's Alzheimer's disease drug fails in late-stage trial
* Baxter to stop late-stage studies of the drug for mild to moderate Alzheimer's
BRIEF-Baxter shares down after drug fails in late-stage trial
NEW YORK, May 7 - Baxter International Inc : * Shares down 2.6 percent in premarket trade after alzeheimer's drug fail
Baxter's Alzheimer's disease drug fails in late-stage trial
May 7 - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities.
Competitors
| Price | Change | |
|---|---|---|
| Boston Scientific Corporation (BSX.N) | $11.15 | +0.23 |
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Wyeth Limited (WLED.NS) | Rs666.25 | -19.05 |
| Hospira, Inc. (HSP.N) | $42.03 | +1.33 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Trading Report for (BAX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

